BMND07

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders. It is being developed by Biomind Labs. As of March 2022, it is in phase 1 clinical trials.

BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders. It is being developed by Biomind Labs. As of March 2022, it is in phase 1 clinical trials.

See also

List of investigational hallucinogens and entactogens List of investigational antidepressants

References

External links

Pipeline - Biomind Labs

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372016456 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.